Nordette-28

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Nordette-28

Property Description
Active ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Tablet (28-day regimen)
Pharmacological class Combined Oral Contraceptive (COC)
Common use Prevention of pregnancy
Origin Synthetic Hormones

Nordette-28 is a prescription-only medication whose formulation is clinically recognized for its high efficacy in the prevention of pregnancy. It belongs to the Hormonal Contraceptives pharmacological class, specifically classified as a Combined Oral Contraceptive (COC), a method utilized for family planning and reproductive management. The drug's mechanism relies on a systematic hormonal approach to establish conditions unfavorable for conception.


What Type of Medicine is Nordette-28?

Nordette-28 is a combination hormonal product, designed to supply a fixed, steady dose of both estrogen and progestin throughout the active tablet phase of the cycle. This formulation is termed monophasic, a distinguishing feature that provides a constant daily hormone dose to simplify the body's hormonal adjustment. Its active components are derived from a purely synthetic origin. This specific formulation is one of the most widely used combined oral contraceptive types, typically prescribed to women of reproductive potential seeking daily, predictable birth control.


Composition and Form: The Combination of Synthetic Hormones

The core composition of Nordette-28 features two key active ingredients: the synthetic estrogen Ethinyl Estradiol and the synthetic progestin Levonorgestrel. These two compounds serve as the essential synthetic steroid foundation for this contraceptive purpose. The medicine is packaged for a standard 28-day regimen in an oral tablet form, which includes 21 active tablets and seven hormone-free (inert) tablets. This structured regimen, which maintains the user's daily habit, ensures the continuous, predictable hormonal signal necessary for effective contraception.

Regulatory References

  1. National Institutes of Health (NIH)
Advertisements

What side effects are possible with Nordette-28?

Possible Side Effects and Safety Information

The official regulatory documentation for combined oral contraceptives containing Ethinyl Estradiol and Levonorgestrel classifies documented adverse effects by the affected System Organ Class (SOC) and frequency of occurrence. These classifications are based on clinical data and regulatory standards, such as those established by the FDA and EMA.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Very Common (occurring in 10% or more of users) include Headache, Nausea/Vomiting, Dysmenorrhea, and Irregular Uterine Bleeding (breakthrough bleeding or spotting). Effects classified as Common (1% to less than 10%) often involve the Gastrointestinal System (Abdominal Pain) and Nervous System (Migraine, Dizziness), as well as Weight Increased and Breast Pain or tenderness.

Serious Adverse Reactions and Key Safety Constraints

Use of this medication is associated with an increased risk of several Serious Adverse Reactions, predominantly involving the Vascular System. These include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thrombotic Events, including Myocardial Infarction (Heart Attack) and Stroke. The risk of VTE is documented as highest during the first year of use or upon re-initiation after a break of four weeks or more.

Specific safety restrictions apply to certain populations and concomitant medications. The medication is contraindicated in females over 35 who smoke due to a significantly increased risk of serious cardiovascular events. Furthermore, it is contraindicated with certain Hepatitis C drug combinations due to the potential for significant liver enzyme elevations.

Advertisements

Overdose and Emergency Response

An overdose with Nordette-28, a combined oral contraceptive containing Ethinyl Estradiol and Levonorgestrel, is officially documented by regulatory authorities as typically resulting from the ingestion of an excessive number of tablets. Official government prescribing information consistently states that acute overdose is generally not associated with serious, life-threatening adverse effects. Nevertheless, specific clinical manifestations related to the hormonal content are consistently listed.

The most commonly documented signs involve the gastrointestinal system, specifically nausea and vomiting. A key anticipated hormonal effect is the potential for withdrawal bleeding or spotting. This type of vaginal bleeding is a specific consideration documented for cases of accidental ingestion in prepubertal girls.

Mandated Emergency Actions Authorities mandate that any suspected or known overdose requires the user to seek immediate medical attention and contact a poison control center or emergency services. Because no specific antidote is known for the synthetic hormones, the management officially described is limited to providing symptomatic and supportive treatment. Clinical monitoring and observation are required to ensure stabilization following the event.

Advertisements

Therapeutic Uses of Nordette-28

Quick Facts

  • Primary Use: Supports the avoidance of conception
  • Associated Benefits: May help establish more predictable monthly cycles
  • Associated Benefits: May help lessen heavy blood flow and painful menstrual discomfort

Nordette-28 is a prescription medication utilized by females of reproductive potential to support the prevention of pregnancy. This medication is a form of hormonal contraception, which is a recognized option for planned family management.

In addition to its primary use, this therapeutic option may provide other benefits related to the menstrual cycle. Clinical experience suggests that use of this product may help contribute to more predictable and manageable monthly cycles. It may also help in mitigating heavy blood loss and discomfort experienced during menstruation, which can support overall well-being. Furthermore, some patients find that this treatment may assist in managing concerns related to ovarian cysts and acne.

Advertisements

Eligibility and Restrictions for Use

Nordette-28 is indicated for use by postpubertal females of reproductive potential for the prevention of pregnancy. Eligibility for use is strictly defined by regulatory authorities and is determined by a comprehensive assessment of pre-existing health conditions, as combined oral contraceptives are associated with specific risks.

Absolute Contraindications The medication is strictly prohibited for women over 35 who smoke, due to a significantly increased risk of serious cardiovascular events. It is also contraindicated in individuals with a high risk of thrombotic diseases, including a history of deep-vein thrombosis, uncontrolled hypertension, or diabetes with vascular complications. Further prohibitions include known or suspected estrogen-dependent cancers (such as breast carcinoma), severe active liver disease or tumors, and undiagnosed abnormal uterine bleeding. The medication is also contraindicated during a known or suspected pregnancy.

Restrictions and Limitations Nordette-28 is not indicated for use before menarche or in postmenopausal women, as safety and efficacy data are not established for these groups. Use requires temporary cessation (discontinuation at least four weeks before and through two weeks after) major surgery or prolonged immobilization to mitigate clotting risk. For non-breastfeeding women, initiation is restricted to no earlier than four weeks after delivery.

Advertisements

What should I know about interactions with other medicines?

Nordette-28, a combined oral contraceptive, has officially documented interaction patterns that primarily affect its efficacy or create specific safety risks when co-administered with other medicines or substances. The regulatory profile establishes several mandatory administration constraints.


Prohibited Combinations and Restrictions

Co-administration is contraindicated with certain Hepatitis C drug regimens (containing Ombitasvir / Paritaprevir / Ritonavir pm Dasabuvir or Glecaprevir/Pibrentasvir) due to the documented risk of significant transaminase elevations. The co-administration with oral Tranexamic Acid is also prohibited due to an additive thromboembolic risk. For major surgery or prolonged immobilization, the product must be discontinued at least four weeks prior to the procedure and for two weeks afterward, as specified in regulatory labeling.

Exposure and Efficacy-Altering Interactions

The effectiveness of Nordette-28 can be decreased by concurrent use with certain enzyme-inducing agents, such as specific anticonvulsants (e.g., Phenytoin, Carbamazepine) and the herbal product St. John's wort. This pharmacokinetic interaction increases the clearance of the hormones. Conversely, the product may increase the plasma concentrations of co-administered drugs like Cyclosporine and significantly reduce the plasma concentration of Lamotrigine. In cases of severe gastrointestinal symptoms like vomiting or diarrhea, regulatory documents treat the resulting impaired absorption as a potential failure, requiring additional contraceptive measures.

Advertisements

Mechanism of Action

Nordette-28, a combination of ethinyl estradiol (estrogen analog) and levonorgestrel (progestin analog), modulates the hypothalamic-pituitary-ovarian axis. The primary biological targets are the progesterone and estrogen receptors in the hypothalamus, pituitary gland, cervix, and endometrium.

Levonorgestrel acts as an agonist at the progesterone receptor, and ethinyl estradiol acts as an agonist at the estrogen receptor. The sustained presence of these synthetic hormones exerts a negative feedback on the hypothalamus, suppressing the pulsatile release of gonadotropin-releasing hormone (GnRH).

This reduced GnRH signaling to the anterior pituitary causes a downstream cascade, leading to a significant suppression of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The suppression of FSH prevents follicular development within the ovaries, and the suppression of the LH surge prevents the rupture and release of a viable oocyte (ovulation).

At the cervical level, levonorgestrel directly modifies the cervical mucus, increasing its viscosity and creating a physical barrier to sperm migration into the upper reproductive tract. Concurrently, the hormonal action induces atrophic changes in the endometrium, diminishing its proliferative state. These system-level physiological modulations collectively define the drug's mechanism.

Advertisements

Dosage and Administration Information

Administration Guidelines for Nordette-28

The administration of Nordette-28 is structured as a 28-day continuous oral regimen.

Instruction Detail
Route of Administration The medicine is administered orally by swallowing the tablet whole.
Dosing Schedule One tablet daily for 28 consecutive days. The pack contains 21 active tablets, each with a fixed dose of 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol, followed by 7 hormone-free (inert) tablets.
Timing and Frequency The tablet must be taken once daily at approximately the same time each day to ensure consistent hormonal levels. Administration is generally without regard to meals, though some instructions suggest taking it after the evening meal or at bedtime.
Population Rules Use of the product is not indicated before menarche. For non-lactating females after childbirth, administration should commence no earlier than four weeks postpartum.
Missed-Dose Protocol Procedures for missed doses vary based on the number of active tablets missed and the cycle week. Missing active tablets may necessitate the use of a nonhormonal back-up method for 7 consecutive days.

Use-Context and Procedural Structure

The core usage protocol is defined by the cyclic pattern and the mandatory adherence to tablet sequence. The 28-day cycle must be followed continuously: once the final inert tablet is taken, a new pack must be started the very next day, with no intentional break between cycles. Initiation of the first cycle follows two options, typically a Day 1 Start or a Sunday Start, with a nonhormonal back-up method required during the initial 7 days if not starting on Day 1. This structured daily commitment is the primary procedural requirement for the proper administration of this monophasic COC.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nordette-28

Research Exploring the Occurrence of Pregnancy

Research has explored this type of combined oral contraceptive (COC) through clinical studies and regulatory analyses that were designed to evaluate outcomes related to the occurrence of pregnancy. Researchers were focused on measuring contraceptive failure, which is often calculated using a standardized outcome measure known as the Pearl Index (reporting the number of pregnancies occurring per 100 woman-years of use).

Trials reported measurements of the Pearl Index that were consistent with the anticipated results when usage adhered strictly to the protocol (often called "perfect use"). However, research highlights that in real-world settings, the failure rate is often influenced by factors related to daily patient adherence. What remains uncertain is the precise real-world failure rate for every individual, as the results reported in controlled trials reflect a rate specific to the study conditions.


Research on Associated Menstrual Cycle Benefits

Research has also explored this type of combined pill in the context of symptoms related to the menstrual cycle. This evidence base includes Randomized Controlled Trials (RCTs) and Systematic Reviews that examined outcomes related to conditions such as painful periods (primary dysmenorrhea) and heavy blood flow (menorrhagia). Researchers monitored outcomes related to pain severity scores and menstrual blood loss volume.

Studies report how symptoms evolved in the observed populations. For example, trials described patterns where measurements of pain medication use and subjective symptom scores evolved over the observed period. Reported outcomes for menstrual blood loss also provided measurements of volume over the course of the study period.


What Remains Unclear or Under Study

While this type of contraception has been extensively studied, certain areas still carry limited data. Long-term follow-up data specifically focused on symptom relief for this exact dose combination is limited when compared across various combined pill formulations. Furthermore, comparative evidence is lacking to definitively position this specific dose against every newer hormonal regimen. Research continues to explore how measured outcomes may differ across varied populations, such as women with a higher Body Mass Index (BMI).

Key Studies & References NIH/MedlinePlus Drug Information: Levonorgestrel and Ethinyl Estradiol

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nordette-28 (FAQ)


Q: What is the general chance of an unintended pregnancy if Nordette-28 is used as described in official materials?

Studies of combined oral contraceptives indicate the chance of unintended pregnancy varies depending on consistency of use. When the pill is taken exactly as directed, often referred to as 'perfect use,' the failure rate is reported as very low—about 0.3 pregnancies per 100 women during the first year. The rate for 'typical use,' which includes inconsistent tablet-taking, is often cited in medical literature as approximately 7 pregnancies per 100 women in the first year.


Q: What is the purpose of the 7 'reminder' pills in the 28-day pack?

The 7 hormone-free, or 'inert,' tablets are included in the 28-day regimen to help a user maintain a consistent, daily routine. Official documents state that maintaining this daily routine helps ensure patient adherence to the dosing schedule, which is critical for the product's effectiveness.


Q: Does the efficacy of Nordette-28 change if a user experiences vomiting?

Yes, severe gastrointestinal symptoms such as vomiting or severe diarrhea may interfere with the body's absorption of the hormones. Regulatory guidance indicates that this situation should be treated similarly to a missed dose of an active tablet. Official information indicates that this situation may necessitate the use of additional nonhormonal contraceptive measures.


Q: Is it true that Nordette-28 can cause weight changes?

Official adverse event reports state that changes in weight are a possible effect of taking this medication. This includes reports of both weight gain (increased weight) and weight decrease. According to studies, weight increase is a Common side effect, meaning it occurs in 1% to less than 10% of users.


Q: What are the components of the 'inactive' pills in the Nordette-28 pack?

The reminder tablets are hormone-free but contain inactive ingredients to make up the tablet structure. These ingredients may include substances such as lactose, magnesium stearate, and specific coloring agents like D&C Red 30 and FD&C Yellow 6.


Q: What are the general guidelines for using Nordette-28 after giving birth?

Guidelines are different depending on breastfeeding status. For non-lactating females (those who are not breastfeeding), official prescribing information states that initiation should be no earlier than four weeks postpartum. For individuals who are breastfeeding, the use of combined hormonal contraceptives is generally a topic of discussion with a healthcare provider, as the hormones can be transferred into breast milk and may potentially affect milk supply.


Q: Does Nordette-28 have an expiration date that needs to be checked?

Yes, the product is packaged with an expiration date (EXP) printed on the packaging. To maintain the stated stability and efficacy of the medication, the blister pack must be stored and used only until that expiration date.


Q: Is there a difference in effectiveness if Nordette-28 is taken at different times of the day?

The regulatory administration instructions emphasize taking the tablet at approximately the same time each day. This consistent timing is necessary to ensure stable hormonal levels in the body, which is essential for the product’s intended effect.


Q: Why is it described that Nordette-28 can be less effective in people with a higher body mass index?

Some regulatory warnings associated with this type of combined hormonal contraceptive state that individuals with a high Body Mass Index (BMI) of 30 kg/m^2 or greater may experience reduced effectiveness. This observation has led to specific warnings being included in regulatory documents.


Q: Are changes in eyesight a known side effect mentioned in official documents for Nordette-28?

Official warnings indicate that a patient should seek immediate medical attention if symptoms such as blurred vision, difficulty in reading, or any other change in sight occur, as these symptoms may be associated with rare, serious vascular events.


Q: What is known about the return of normal ovulation after stopping Nordette-28?

The mechanism of the drug involves suppressing ovulation. After discontinuing this type of hormonal contraception, there is typically a return to normal ovulatory function. The time it takes for fertility to return can vary among different users.


Q: Can taking Nordette-28 cause a false positive result on certain medical tests?

Yes, regulatory documentation states that the results of some medical tests may be affected by the use of this medication. This is why a healthcare provider should be informed of its use before certain tests are conducted.


Q: Does Nordette-28 have effects on hair growth or hair loss?

Dermatologic adverse effects have been reported in association with the use of this medication. These reports include instances of both alopecia (hair loss) and hirsutism (excessive hair growth).


Q: Are there official descriptions of the effects of Nordette-28 on libido?

Changes in sexual function have been reported in official documents, though the frequency is not precisely known. These reported effects include a decreased interest in sexual intercourse or a loss in sexual ability, desire, drive, or performance.


Q: How often is diarrhea mentioned as a possible side effect in clinical trial data for Nordette-28?

Diarrhea is listed as a Common side effect for this combination of hormones. Common effects are those reported to occur in approximately 1% to 10% of users in clinical data.


Q: What type of monitoring, like blood tests, is typically recommended while on Nordette-28?

Regulatory guidance suggests that a healthcare provider should check a patient's progress through regular visits. Based on a patient's health status, and the provider determines if specific checks, such as blood pressure monitoring or certain blood and urine tests, are warranted.


Q: Is it important to have a period every month while taking Nordette-28?

The bleed that occurs during the use of the hormone-free tablets is a withdrawal bleed caused by the temporary drop in hormone levels. The primary function of the inert pills is to maintain the daily routine. While a bleed is expected, irregular bleeding can be common, but persistent or concerning changes in bleeding patterns are generally assessed by a healthcare provider.


Q: Are there different generic versions of Nordette-28, and how do they compare?

Yes, regulatory agencies like the FDA have approved generic versions of the ethinyl estradiol/levonorgestrel combination. Generic products approved under the same therapeutic category and strength are typically considered therapeutically equivalent (AB-rated) to the brand name product.


Q: What should a patient do if they experience breast tenderness while on Nordette-28?

Breast tenderness is documented as a Common side effect. The general approach described in regulatory guidance is to notify a healthcare provider if the side effect persists or worsens over time, or if the tenderness becomes severe.

Advertisements

How should Nordette-28 be stored and disposed of?

Storage and Disposal of Nordette-28

Official Storage Conditions

Nordette-28 must be stored at Controlled Room Temperature, which is officially defined as a range where the temperature is maintained below 25 C (77 F). The medication must be kept in its original blister pack and stored in a cool, dry place to ensure protection from light, moisture, and excessive heat.

Constraint Requirement
Temperature Below 25 C (Controlled Room Temperature)
Environment Protect from heat, light, and dampness

Product Protection and Disposal

The most critical storage rule is to ensure the product is kept out of the sight and reach of children, often mandating storage in a secured, high location. To maintain product stability, the tablets should not be taken past the expiration date (EXP) printed on the packaging.

For disposal, unused, expired, or damaged Nordette-28 must not be thrown into household trash or wastewater. Instead, patients are officially instructed to consult a pharmacist to return the medication for regulated pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nordette-28 found in:

A-Z Index: